A Phase III Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Study Status

Open to Enrollment

Study Description

The purpose of this clinical trial is to determine the effectiveness of the experimental drug onartuzumab (also called MetMab) in combination with mFOLFOX6 chemotherapy in treating HER2-negative gastric cancer.

Receptors are specific sites on the surface of cancer cells that tell the cell to do something, such as grow, divide, spread, or other actions. The Met receptor has been shown to be important in the growth and spread of cancer cells. Onartuzumab is monoclonal antibody (a type of protein commonly made by the immune system) that attaches to the Met receptor and prevents Met from activating tumor cells. Therefore onartuzumab combined with chemotherapy may help slow the spread of gastric cancer.

Study participants will be randomly assigned to one of two study arms:

  • Arm A: Onartuzumab via infusion  + mFOLFOX6 chemotherapy
  • Arm B: Placebo (an inactive substance) via infusion  + mFOLFOX6 chemotherapy

Participants will receive the chemotherapy with either onartuzumab or placebo for 12 cycles. Each cycle is 14 days. For participants whose tumor has decreased in size or remained stable after completing these 12 cycles, they may continue to receive onartuzumab or placebo without the mFOLFOX6 chemotherapy until they are no longer responding to treatment.

Disease Status and/or Stage

Metastatic Gastric Cancer



Key Eligibility

  • Age 18 and older
  • Gastric cancer
  • Inoperable, metastatic disease
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Manish Shah, MD


  • Alice Mercado, RN
  • (212) 746-5430
  • [email protected]
  • GI Oncology Medical Practice
  • 646-962-6200

Protocol ID


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page